Highlights – LSE:HIK

• Hikma will appoint Umang Vohra as an independent non-executive director with effect from 1 December 2026.

• Vohra will also join Hikma's Audit Committee and its Nomination and Governance Committee on appointment.

• The former Cipla chief executive currently serves as Executive Chairman and Group CEO of Cohance Lifesciences.

• The appointment follows Hikma's 5 November update, which narrowed 2026 operating profit guidance to $740m-$760m.

Portfolio choices, Manufacturing reach and the US market sit at the heart of the generics business, and Hikma Pharmaceuticals (LSE: HIK) is adding a boardroom voice with experience in all three. In an announcement at 07:00 on 9 November 2026, the London-listed pharmaceutical group said Umang Vohra, who ran India's Cipla for close to a decade, will join its board as an independent non-executive director.

The appointment in brief

Vohra's appointment takes effect on 1 December 2026. He will also become a member of Hikma's Audit Committee and its Nomination and Governance Committee. The company pointed to his experience in North America and his expertise in contract development and manufacturing (CDMO) and generics.

Hikma's board said it expects his background in growth, innovation and portfolio transformation to strengthen its strategic oversight, and to support mergers and acquisitions as well as operational execution.

A career built in generics

Vohra is currently Executive Chairman and Group CEO of Cohance Lifesciences, taking the chair on 1 May 2026 and the group chief executive role on 20 May 2026. According to Cohance's published biography, he joined Cipla in 2015 as Global Chief Financial and Strategy Officer before becoming Managing Director and Global Chief Executive Officer in 2016.

Before Cipla, he spent more than 14 years at Dr. Reddy's Laboratories, latterly as Chief Financial Officer and Head of North America Generics. An earlier role at PepsiCo India focused on financial strategy and Business planning. He holds a bachelor's degree in computer science engineering and an MBA.

Boardroom changes at Hikma

The appointment adds to a period of change at the top of the FTSE 250 drugmaker. In September, Hikma named Rebecca Hall, previously Chief Financial Officer of ViiV Healthcare, as its next CFO and an executive director. Khalid Nabilsi is due to leave the board on 31 December 2026 while remaining on the executive committee as Deputy CEO for North America and Europe. Hikma's 5 November trading statement confirmed that Hall will join on 8 March 2027.

Where the business stands

That trading statement narrowed 2026 operating profit guidance to between $740 million and $760 million, from $720 million to $770 million, and reiterated Revenue growth of 2% to 4%. Branded revenue growth guidance was raised to about 10%, from 6% to 8%, and its core Operating Margin is now expected to be close to 27%, up from about 25%. Meanwhile, Injectables revenue is now expected to be broadly flat. Hikma Rx revenue is also expected to be broadly flat, with a core operating margin close to 20%. The group completed its $250 million share buyback, repurchasing 13,138,823 shares.

Chief Executive Said Darwazah said: "We are seeing strong momentum at Hikma, delivering on the commitments we made at the beginning of the year."

Things shareholders may monitor

Hikma moved from the FTSE 100 to the FTSE 250 in the March 2026 quarterly review, and its shares now trade among mid-cap healthcare names on the UK stock market. Investors following the board refresh may look at how committee responsibilities shift once Vohra joins, the handover between Nabilsi and Hall, and any strategic or deal activity in which the board's added generics and CDMO expertise becomes relevant. Pricing pressure in US Injectables, noted in the latest trading statement, remains a Factor alongside the stronger Branded performance.

Fresh experience for a changing board

The arrival of a former generics chief executive gives Hikma's non-executive bench direct operating experience of the North American generics market. With a new CFO due in March and an executive director stepping off the board at year-end, the make-up of the board will have changed in several places by early 2027.